OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer

被引：0
|
作者：
Nicum, S. [1 ]
Strauss, V. Y. [2 ]
McGregor, N. [3 ]
McNeish, I. [4 ]
Roux, R. [1 ]
Hall, M. [5 ]
Michael, A. [6 ]
Roberts, C. [2 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
[2] Univ Oxford, Ctr Stat Med, Oxford, England
[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England
[4] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[5] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Stevenage, Middx, England
[6] Univ Surrey, Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
989TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
    Mansouri, Anita
    McGregor, Naomi
    Dunn, Rachel
    Dobbie, Sam
    Holmes, Jane
    Collins, Linda
    Nicum, Shibani
    BMJ OPEN, 2021, 11 (01):
  • [2] Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
    Nicum, S.
    Holmes, J.
    McGregor, N.
    Dunn, R.
    Collins, L.
    Kaye, S.
    McNeish, I.
    Glasspool, R. M.
    Hall, M.
    Roux, R.
    Michael, A.
    Banerjee, S.
    Kristeleit, R.
    Jayson, G.
    Clamp, A.
    Mansouri, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S725 - S726
  • [3] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Shibani Nicum
    Naomi McGregor
    Rachel Austin
    Linda Collins
    Susan Dutton
    Iain McNeish
    Rosalind Glasspool
    Marcia Hall
    Rene Roux
    Agnieszka Michael
    Andrew Clamp
    Gordon Jayson
    Rebecca Kristeleit
    Susana Banerjee
    Anita Mansouri
    British Journal of Cancer, 2024, 130 : 941 - 950
  • [4] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Nicum, Shibani
    Mcgregor, Naomi
    Austin, Rachel
    Collins, Linda
    Dutton, Susan
    Mcneish, Iain
    Glasspool, Rosalind
    Hall, Marcia
    Roux, Rene
    Michael, Agnieszka
    Clamp, Andrew
    Jayson, Gordon
    Kristeleit, Rebecca
    Banerjee, Susana
    Mansouri, Anita
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 941 - 950
  • [5] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [6] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [7] ORZORA: OPEN-LABEL PHASE IV TRIAL OF OLAPARIB IN PATIENTS WITH BRCA-MUTATED OVARIAN CANCER
    Pignata, S.
    Lewis, J.
    Tchakov, I.
    Robertson, J. D.
    Morris, T.
    Jayawardene, D.
    Tyczynski, J. E.
    Hodgson, D. R.
    Mills, J.
    Di Maio, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1469 - 1470
  • [8] The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
    Wibisono, M. G.
    Wibisono, M. H.
    Sabran, M. Z.
    Wibisono, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1404
  • [9] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Nozawa, Kazuki
    Yoshimura, Akiyo
    Iwata, Hiroji
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1439
  • [10] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
12345